These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32722648)

  • 1. Short Chain Fatty Acids Effect on Chloride Channel ClC-2 as a Possible Mechanism for Lubiprostone Intestinal Action.
    Catalán MA; Julio-Kalajzić F; Niemeyer MI; Cid LP; Sepúlveda FV
    Cells; 2020 Jul; 9(8):. PubMed ID: 32722648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional Role of Basolateral ClC-2 Channels in the Regulation of Duodenal Anion Secretion in Mice.
    Du C; Liu J; Wan H; Dong H; Zhao X
    Dig Dis Sci; 2019 Sep; 64(9):2527-2537. PubMed ID: 30874987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lubiprostone is non-selective activator of cAMP-gated ion channels and Clc-2 has a minor role in its prosecretory effect in intestinal epithelial cells.
    Oak AA; Chu T; Yottasan P; Chhetri PD; Zhu J; Du Bois J; Cil O
    Mol Pharmacol; 2022 Jun; 102(2):106-15. PubMed ID: 35680165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaceutical Activation or Genetic Absence of ClC-2 Alters Tight Junctions During Experimental Colitis.
    Jin Y; Pridgen TA; Blikslager AT
    Inflamm Bowel Dis; 2015 Dec; 21(12):2747-57. PubMed ID: 26332307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiation between human ClC-2 and CFTR Cl- channels with pharmacological agents.
    Cuppoletti J; Chakrabarti J; Tewari KP; Malinowska DH
    Am J Physiol Cell Physiol; 2014 Sep; 307(5):C479-92. PubMed ID: 25009109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of the fatty acid activation site on human ClC-2.
    Cuppoletti J; Tewari KP; Chakrabarti J; Malinowska DH
    Am J Physiol Cell Physiol; 2017 Jun; 312(6):C707-C723. PubMed ID: 28424169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lubiprostone protects esophageal mucosa from acid injury in porcine esophagus.
    Krüger L; Pridgen TA; Taylor ER; Garman KS; Blikslager AT
    Am J Physiol Gastrointest Liver Physiol; 2020 Apr; 318(4):G613-G623. PubMed ID: 32068440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methadone but not morphine inhibits lubiprostone-stimulated Cl- currents in T84 intestinal cells and recombinant human ClC-2, but not CFTR Cl- currents.
    Cuppoletti J; Chakrabarti J; Tewari K; Malinowska DH
    Cell Biochem Biophys; 2013 May; 66(1):53-63. PubMed ID: 22918821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents.
    Cuppoletti J; Malinowska DH; Tewari KP; Li QJ; Sherry AM; Patchen ML; Ueno R
    Am J Physiol Cell Physiol; 2004 Nov; 287(5):C1173-83. PubMed ID: 15213059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A synthetic prostone activates apical chloride channels in A6 epithelial cells.
    Bao HF; Liu L; Self J; Duke BJ; Ueno R; Eaton DC
    Am J Physiol Gastrointest Liver Physiol; 2008 Aug; 295(2):G234-51. PubMed ID: 18511742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut microbial and short-chain fatty acid profiles in adults with chronic constipation before and after treatment with lubiprostone.
    Kang DW; DiBaise JK; Ilhan ZE; Crowell MD; Rideout JR; Caporaso JG; Rittmann BE; Krajmalnik-Brown R
    Anaerobe; 2015 Jun; 33():33-41. PubMed ID: 25617726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator.
    Bijvelds MJ; Bot AG; Escher JC; De Jonge HR
    Gastroenterology; 2009 Sep; 137(3):976-85. PubMed ID: 19454284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lubiprostone activates CFTR, but not ClC-2, via the prostaglandin receptor (EP(4)).
    Norimatsu Y; Moran AR; MacDonald KD
    Biochem Biophys Res Commun; 2012 Sep; 426(3):374-9. PubMed ID: 22960173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the ClC-2 chloride channel, lubiprostone.
    Moeser AJ; Nighot PK; Engelke KJ; Ueno R; Blikslager AT
    Am J Physiol Gastrointest Liver Physiol; 2007 Feb; 292(2):G647-56. PubMed ID: 17053162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lubiprostone activates non-CFTR-dependent respiratory epithelial chloride secretion in cystic fibrosis mice.
    MacDonald KD; McKenzie KR; Henderson MJ; Hawkins CE; Vij N; Zeitlin PL
    Am J Physiol Lung Cell Mol Physiol; 2008 Nov; 295(5):L933-40. PubMed ID: 18805957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lubiprostone as a potential therapeutic agent to improve intestinal permeability and prevent the development of atherosclerosis in apolipoprotein E-deficient mice.
    Arakawa K; Ishigami T; Nakai-Sugiyama M; Chen L; Doi H; Kino T; Minegishi S; Saigoh-Teranaka S; Sasaki-Nakashima R; Hibi K; Kimura K; Tamura K
    PLoS One; 2019; 14(6):e0218096. PubMed ID: 31206525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Negative chronotropic and inotropic effects of lubiprostone on iPS cell-derived cardiomyocytes via activation of CFTR.
    Akita H; Yoshie S; Ishida T; Takeishi Y; Hazama A
    BMC Complement Med Ther; 2020 Apr; 20(1):118. PubMed ID: 32306956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic stress and intestinal permeability: Lubiprostone regulates glucocorticoid receptor-mediated changes in colon epithelial tight junction proteins, barrier function, and visceral pain in the rodent and human.
    Zong Y; Zhu S; Zhang S; Zheng G; Wiley JW; Hong S
    Neurogastroenterol Motil; 2019 Feb; 31(2):e13477. PubMed ID: 30284340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ClC-2 and intestinal chloride secretion.
    Flores CA
    Am J Physiol Gastrointest Liver Physiol; 2016 Oct; 311(4):G775. PubMed ID: 27829212
    [No Abstract]   [Full Text] [Related]  

  • 20. Lubiprostone prevents nonsteroidal anti-inflammatory drug-induced small intestinal damage by suppressing the expression of inflammatory mediators via EP4 receptors.
    Hayashi S; Kurata N; Yamaguchi A; Amagase K; Takeuchi K
    J Pharmacol Exp Ther; 2014 Jun; 349(3):470-9. PubMed ID: 24713141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.